The post VitalConnect Secures over $30 Million in Oversubscribed Series F Financing first appeared on EW Healthcare Partners.
]]>SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed Series F financing in excess of $30 million. The financing round was led by Revelation Partners with significant participation from the company’s existing investors, including Pacific General Ventures and EW Healthcare Partners. The additional funding will support VitalConnect’s rapidly growing remote cardiac monitoring business while advancing key partnerships with the largest hospital systems in the United States to provide remote patient monitoring in an in-patient setting.
“VitalConnect’s services have been widely adopted at an accelerated pace over the past 24 months, enabling our revenue to triple from 2021 to 2022, and putting us on track to nearly double revenue again in 2023. We are also experiencing significant EBITDA improvement and we expect to achieve profitability in 2024,” said Peter Van Haur, CEO of VitalConnect. “This latest round of financing, at an increased valuation, signals unwavering support from our investors while providing the company the runway needed to achieve our goal of being the world’s leading provider of remote patient monitoring solutions.”
“Revelation Partners is excited to join the distinguished list of VitalConnect investors to help further accelerate the company’s already impressive growth,” said Fred Lee, Partner at Revelation Partners. “VitalConnect is in the unique position of being able to meaningfully participate in multiple billion-dollar markets that are growing at double-digit rates. The adoption of the technology in the marketplace, thus far, has been unprecedented, thereby giving us confidence in the leadership team’s ability to execute. We are committed to supporting the organization to enable them to maximize both revenue and profitability.”
Founded in 2011, VitalConnect has deployed hundreds of thousands of biosensors throughout the world, including leading healthcare facilities such as Brigham and Women’s, Hackensack Medical Center, Northwell Health and John Radcliffe Hospital-Oxford University. The VitalPatch allows real-time remote or in-hospital monitoring, allowing physicians to optimize the delivery of care to their patients.
About VitalConnect, Inc.
VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. VitalConnect’s advanced, yet easy-to-use, platform, was designed to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers. For more information: www.vitalconnect.com.
About Revelation Partners
Revelation Partners provides flexible capital solutions to the healthcare ecosystem. These customized solutions provide liquidity, align shareholders, and support the growth of privately-held healthcare companies. The firm’s long-term approach allows it to address the issues faced by a wide range of counterparties, including founders, company management teams, institutional investors (including general partners), and limited partners. For more information: www.revelation-partners.com.
Contacts
Media Contacts:
Steve Kelly
VitalConnect, Inc.
206-856-6488
[email protected]
Fred Lee
Revelation Partners
415-308-3896
[email protected]
The post VitalConnect Secures over $30 Million in Oversubscribed Series F Financing first appeared on EW Healthcare Partners.
]]>The post Grundium Oy Announces the Appointment of Head of the US Business and Two Independent Board Members first appeared on EW Healthcare Partners.
]]>Josh Griffith joins Grundium bringing 18+ years of sales and marketing experience in the global diagnostics industry driving capital equipment, consumable, and royalty revenues. Prior to joining Grundium Josh served as Vice President Global Marketing at Luminex – A DiaSorin Company.
Andy Thomson brings more than three decades of commercial and leadership experience to the board of Grundium. As a seasoned executive, Andy has spent significant time across the diagnostics and life sciences space through a career at three large companies. He has served as SVP EMEA and SVP and Group President of specialty Diagnostics at Thermo Fisher. Prior to joining Thermo, he was SVP and General Manager of the Centralised Diagnostics division at Roche. Before joining Roche, Andy was VP of Marketing at Dade Behring. In addition to the board of Grundium, Andy currently serves on the Boards of TubeWriter, ClearStart Inc. and Spectrum Solutions.
Chris Linthwaite is a life sciences veteran who brings experience across tools diagnostics and genomics. He is currently Chief Executive Officer at Scram Systems. Prior to joining Scram, Chris served as CEO of Fluidigm, since 2016. Prior to joining Fluidigm in 2016, Chris served as President of the Genetic Sciences platform at Life Technologies, managing four technology platforms across Genetic, Medical and Applied Sciences Division.
“We are excited to welcome Josh to the Grundium team and Andy and Chris to our board of directors. Josh’s high energy and in-depth knowledge in the IVD and research market will be fundamental in leading our sales and marketing operations in the US to leverage the potential of our unique product and technology portfolio. We have wanted to establish a footprint in the US since we founded Grundium and I’m happy to establish our US operations with Josh at the helm” said Mika Kuisma, Grundium CEO.
“We are thrilled to welcome Josh to the team and are excited to be able to work with Andy and Chris as we aggressively expand the business in the US and in the human digital pathology space. Andy and Chris’ deep expertise in life sciences tools global businesses will be invaluable to our board as we grow the business and expand the operations in particular in the US,” said Evis Hursever, Managing Director at EW Healthcare Partners and Chair of the Board of Directors.
About Grundium Oy
A leader in advanced imaging technology, Grundium makes digital pathology and best professional diagnosis available for all life – whether human, animal, plant or other. This is achieved by applying state-of-the-art mobile technology in digital pathology. Established in 2015 by ex-Nokia engineers, the Tampere-based company is democratizing digital pathology with the Ocus® microscope scanners. The cutting-edge imaging solutions are based on over 20 years of experience in optics, sensors and beautiful high-precision devices. https://www.grundium.com/
About EW Healthcare Partners
With over $4 billion raised since inception, EW Healthcare Partners makes growth equity investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of senior investment professionals located in their offices in New York, London and Houston. https://ewhealthcare.com/
The post Grundium Oy Announces the Appointment of Head of the US Business and Two Independent Board Members first appeared on EW Healthcare Partners.
]]>The post EW Healthcare Partners Announces Platform Investment in Enercon Technologies first appeared on EW Healthcare Partners.
]]>New York, NY and Gray, ME – EW Healthcare Partners (“EW”) announced today that it has made a platform investment in Enercon Technologies, Inc. (“Enercon” or “the Company”), becoming a majority shareholder in the business. This investment reflects the culmination of months of evaluation on behalf of the Enercon management team and its two co-founders, Walter Hebold and Ronald Marcotte, as they sought a growth-oriented partner with deep industry expertise and a shared vision for Enercon’s future direction.
Founded in 1980, Enercon has grown rapidly under the leadership of its founders and CEO, Ryan Marcotte, into one of the leading contract design, engineering, and manufacturing businesses in the U.S. With particular expertise in product development and precision manufacturing for complex electronics, the Company has attracted a high-quality roster of customers across the medical device, life sciences, and industrial/defense end markets. Enercon’s revenues have more than doubled since 2019, when the Company’s new, state-of-the-art facility came online following $26M of investment by the founders to significantly expand capacity to ~100,000 square feet and support robust demand from customers.
“We are thrilled to partner with the Enercon team to help continue their history of impressive growth, while providing additional resources and investment to further expand upon their innovative offerings for existing and future customers,” said Brooks Andrews, Managing Director at EW Healthcare Partners. “Feedback from the market was clear in our diligence – Enercon excels when it comes to engineering and manufacturing capabilities, quality, and reliably serving its customers’ needs – and we look forward to increasing the awareness of these core strengths in the years ahead.”
“Enercon is excited to partner with EW Healthcare for the next stage of our company’s growth,” said Ryan Marcotte, CEO at Enercon Technologies. “EW enhances Enercon’s already strong financial and operational position by providing expertise in Enercon’s core end markets of Healthcare and MedTech. EW shares our vision of growing Enercon as a platform and they align with our values and culture that our employees are our most important asset. We are thrilled to have EW as our partner.”
Kirkland & Ellis acted as legal advisor, PwC as financial due diligence and tax advisor, and BCG as commercial due diligence advisor for EW. BDO Capital Advisors, LLC served as financial advisor to Enercon and its shareholders.
About Enercon Technologies, Inc.
Enercon Technologies is an award-winning provider of electronic product development and manufacturing services to leading OEMs in the Medical Device, Life Sciences, Industrial and Defense end markets. Enercon builds long-term relationships with its customers through its Design+Build model which aligns goals, results in a faster time-to-market, and optimizes product launches. From its purpose-built state-of-the-art facility, Enercon’s intelligent manufacturing services provide efficient and controlled production via automation, robotics and software systems that control and trace materials and processes throughout the factory. Based in Gray, Maine, Enercon is privately owned and financially strong with over 40 years of profitability since its founding in 1980.
About EW Healthcare Partners (“EW”)
With over $4 billion raised since inception, EW Healthcare Partners is one of the oldest and most respected private healthcare investment firms and seeks to make growth equity investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of senior investment professionals located in New York, London and Houston. https://ewhealthcare.com/
The post EW Healthcare Partners Announces Platform Investment in Enercon Technologies first appeared on EW Healthcare Partners.
]]>The post Frost & Sullivan Recognizes VitalConnect with the 2022 New Product Innovation Award for Its Leading-edge Wearable Patient Monitoring Device first appeared on EW Healthcare Partners.
]]>SAN ANTONIO, Texas —— Based on its recent analysis of the wearable biosensor industry, Frost & Sullivan recognizes VitalConnect with the 2022 North America New Product Innovation Award for delivering a world-class biosensor that comfortably monitors patients and detects multiple health problems. VitalConnect has significantly reduced hospital workloads by enabling patients who prefer to move freely or who can be monitored from home to use a comfortable, state-of-the-art cardiac monitoring device with the same effectiveness and quality as hospital or home-based devices.
VitalConnect’s superior health monitoring technologies offer a unique solution that improves patients’ lives and delivers stronger capabilities than the biosensors currently available. VitalConnect creates products that make remote, in-hospital, or patient monitoring a simple and safe activity, giving peace of mind to the patients and delivering never-before-seen capabilities to healthcare providers.
VitalConnect has set itself apart from the competition by offering a higher quality and more efficient product for its patients compared to standard solutions like the Holter monitor. The company’s solutions also provide capabilities comparable to those of an intensive care unit (ICU) with a comfortable, flexible, fully wearable device. The company’s innovation thus revolutionizes the wearable biosensor space.
“With an embedded biosensor, the four-inch medical-grade wearable miniaturizes the observational capabilities of an ICU. The unique cardiac monitoring technology simultaneously examines eight essential patient vitals, looking for 21 different cardiac arrhythmias while sending all patient data to a secure cloud in real-time,” stated Varun Babu, Senior Industry Analyst at Frost & Sullivan. “Traditional cardiac monitoring solutions like the Holter monitor have multiple wires and are difficult to carry due to their weight. Uncomfortable for patients, these solutions often provide suboptimal parameters for doctors to assess.”
VitalPatch is VitalConnect’s flagship product. It is a small, easy-to-wear biosensor that monitors parameters such as heart rate, respiration rate, and body temperature while also detecting arrhythmia. VitalPatch is used in conjunction with VistaCenter, a cloud-based platform where patient-generated data (PGD) is shown in real-time and enables notifications 24/7 to guarantee the patients’ well-being.
VitalConnect has a rapidly growing customer base and a promising future in the wearable biosensor industry. The company has experienced exponential growth and raised $39 million in January 2022 to increase its organizational capabilities, while the clinical-grade wearables industry is quite a favorable environment for growth as it is expected to grow from $13 billion in 2021 to around $41 billion by 2026.
“VitalPatch stores PGD in the cloud, giving physicians full disclosure and real-time access to critical patient information. It advances the level of care as patients do not need an emergency check if they feel unwell before the monitoring period is over,” noted Manuel Albornoz, Best Practices Research Analyst for Frost & Sullivan. “Frost & Sullivan believes VitalConnect is well-positioned to drive the wearable biosensor space into its next growth phase, capturing market share and gaining leadership in the coming years.”
Each year, Frost & Sullivan presents this award to the company that develops an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Lindsey Whitaker P: 1.210.477.8457 E: [email protected]
About VitalConnect, Inc.
VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. VitalConnect’s advanced yet easy-to-use platform, was designed to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers. For more information: www.vitalconnect.com.
Contact:
Steve Kelly P: 1.206.856.6488 E: [email protected]
The post Frost & Sullivan Recognizes VitalConnect with the 2022 New Product Innovation Award for Its Leading-edge Wearable Patient Monitoring Device first appeared on EW Healthcare Partners.
]]>The post BioTissue Completes Name Change first appeared on EW Healthcare Partners.
]]>“For over 25 years, the BioTissue name has been representative of leadership in ocular regenerative healing. Our name change allows us to showcase how our experience and expertise extends into the surgical space under the same trusted brand,” said Ted Davis, president and CEO, BioTissue. “Also, healthcare professionals and their patients can rest assured that we will continue to deliver the same high-quality products on which they rely.”
BioTissue’s innovative amniotic membrane product families Prokera®, AmnioGraft®, AmnioGuard®, Neox®, and Clarix® will retain their trusted brand names. All these products use the company’s proprietary CryoTek® cryopreservation technology designed to retain the tissue’s structural and functional integrity.
Today, nearly 700,000 patients have been treated with BioTissue’s products and its scientific and clinical advancements have been documented in over 390 peer-reviewed publications. BioTissue continues to break new ground with multiple investigational new drug clinical trials underway to secure biologic license applications for specific indications to address unmet clinical needs in the ocular, orthopedics, and wound management markets.
About BioTissue Holdings Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues biologics license applications for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed nearly 700,000 human implants with its products and published over 390 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at www.biotissue.com.
Media Contact
Heather Kowalczyk, APR
or (585) 434-2148
McDougall Communications for BioTissue
The post BioTissue Completes Name Change first appeared on EW Healthcare Partners.
]]>The post EW Healthcare Partners Acquires Germfree Laboratories, Inc. first appeared on EW Healthcare Partners.
]]>New York, NY, and Ormond Beach, FL – EW Healthcare Partners announced today that it has acquired Germfree Laboratories, Inc., a leading US manufacturer of turnkey, mobile and modular cleanrooms and biocontainment facilities, as well as the equipment and services required for critical environments.
Founded in 1962, Germfree has continuously provided advanced solutions for healthcare and life science clients. The company has experienced significant growth over the years, with more than 200 facilities deployed on six continents and nearly 200 employees located in its 173,000 ft2 (16,000 m2), environmentally controlled, manufacturing plant in Ormond Beach, Florida. Germfree’s mobile and modular solutions are well-suited to service major, highly-regulated market segments in Biopharma, Compounding Pharmacy, and Biocontainment.
“There is an increasing demand for mobile and modular cleanrooms in biopharma to keep pace with new technologies and platforms, capacity constraints and the demand for flexible solutions that are delivered quickly,” said Evis Hursever, Managing Director at EW Healthcare Partners. “Germfree is addressing this demand for cleanrooms by designing and manufacturing advanced solutions for specialised and flexible cGMP-compliant manufacturing space. We look forward to working with Kevin and his team to further accelerate the company’s growth into the fast-growing ATMP (advanced therapy medicinal products) sector.”
“Together with EW, Germfree is positioned to maximize and scale our manufacturing to help fill the biomanufacturing capacity gap facing biopharma,” said Kevin Kyle, Germfree’s CEO. “EW is the perfect partner to foster and fuel Germfree’s growth journey. Our shared mission to deliver innovation in healthcare and biopharma, and their commitment to our next stages of growth and long-term success, makes this a tremendous strategic fit. Further, EW’s expertise and experience in advanced therapeutics, and their extensive global network adds synergy, as we expand our solutions to meet the fast-growing demands in segments such as cell and gene therapy.”
Kirkland & Ellis acted as legal adviser, A&M as FDD and tax adviser, and BCG as commercial due diligence adviser for EW Healthcare Partners. Jefferies LLC served as exclusive financial advisor and Holland & Knight LLP acted as legal adviser to Germfree.
About EW Healthcare Partners (“EW”)
With over $4 billion raised since inception, EW Healthcare Partners is one of the oldest and most respected private healthcare investment firms and seeks to make growth equity investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in New York, London and Houston. https://ewhealthcare.com/
About Germfree Laboratories, Inc.
For six decades, Germfree has been creating environments that serve life science innovation and advance global health. The company designs and manufactures mobile and modular cleanrooms and high-containment laboratories, as well as a comprehensive line of biosafety and aseptic processing equipment. Germfree’s bioGO® cleanrooms provide flexible, scalable solutions for biopharma and advanced therapy manufacturing. With over 200 facility installations in 32 countries, Germfree is a global company, committed to enabling its clients to develop new life-saving cures or prevent the next pandemic. The Germfree team provides leading-edge engineering and technology, subject-matter expertise, and a foundation of highly skilled builders, all located at its facility in Ormond Beach, Florida. https://www.germfree.com/
Media Contacts:
Taylor Miller
Email: [email protected]
Phone: (386) 265-4300
Anne DeMaret
Email: [email protected]
Phone: (281) 528 – 1956
The post EW Healthcare Partners Acquires Germfree Laboratories, Inc. first appeared on EW Healthcare Partners.
]]>The post VitalConnect Announces Investment from HCA Healthcare to Accelerate Commercial Growth and Create Strategic Partnership first appeared on EW Healthcare Partners.
]]>SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the completion of an investment funded by Health Insight Capital, the investment arm of HCA Healthcare Inc., (NYSE: HCA), one of the nation’s leading healthcare providers. The investment will go toward further accelerating VitalConnect’s rapidly growing cardiac monitoring business segment while advancing key Remote Patient Monitoring of individuals who have experienced heart failure (HF), chronic obstructive pulmonary disease (COPD) and sepsis, among others. This funding support is expected to help VitalConnect continue bringing the most advanced technology to patients and providers.
“This strategic investment from HCA Healthcare will further accelerate VitalConnect’s expansive growth and upward trajectory in the Cardiac Monitoring space”
“This strategic investment from HCA Healthcare will further accelerate VitalConnect’s expansive growth and upward trajectory in the Cardiac Monitoring space,” said Peter Van Haur, CEO, VitalConnect. “We’ve experienced unparalleled physician adoption and growth over the past 18 months since launch, and HCA Healthcare’s investment will enable us to continue bringing customers the most comprehensive remote patient monitoring platform.”
Founded in 2011, VitalConnect has deployed hundreds of thousands of biosensors throughout the world, including care facilities such as Brigham and Women’s, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital-Oxford University. The VitalPatch allows real-time remote or in-hospital monitoring, allowing physicians to optimize the delivery of care to their patients.
About VitalConnect, Inc.
VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes.
The post VitalConnect Announces Investment from HCA Healthcare to Accelerate Commercial Growth and Create Strategic Partnership first appeared on EW Healthcare Partners.
]]>The post VitalConnect Appoints Amy Covert as Chief Financial Officer first appeared on EW Healthcare Partners.
]]>SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the appointment of Amy Covert to the position of Chief Financial Officer, effective August 8, 2022. Covert brings more than 20 years of experience to the role, in both public and private companies, primarily within healthcare. She joins VitalConnect from HoverTech International, a medical device company, where she had served as CFO since 2019. At HoverTech, Covert had responsibility for finance and accounting as well as the operational organization which included manufacturing, sourcing, customer service and logistics. Prior to HoverTech, she held various financial leadership roles at BioTelemetry, Inc., a remote cardiac monitoring company.
“Amy brings a wealth of experience in building high-performance finance teams and driving organizational change to VitalConnect”.
Covert received her Master of Business Administration and a Certificate in Accountancy from Villanova University. She graduated with a Bachelor of Science in Finance and International Business from The Pennsylvania State University.
“Amy brings a wealth of experience in building high-performance finance teams and driving organizational change to VitalConnect,” said Peter Van Haur, CEO of VitalConnect. “Over the past few years, we’ve attracted tremendous talent to the leadership team with the common goal of improving outcomes for physicians and patients. Adding a strong financial leader with Amy’s experience will allow VitalConnect to accelerate our already rapid growth in cardiac monitoring and remote patient management.”
Founded in 2011, VitalConnect has deployed more than 200,000 patches throughout the world, including to leading acute-care facilities such as Brigham and Women’s Hospital, Hackensack Medical Center, Northwell Health and John Radcliffe Hospital-Oxford University. The VitalPatch allows real-time remote or in-hospital monitoring, allowing physicians to optimize the delivery of care to their patients.
About VitalConnect, Inc.
VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. For more information: www.vitalconnect.com.
Contacts
Media Contacts:
Steve Kelly
VitalConnect, Inc.
206-856-6488
[email protected]
The post VitalConnect Appoints Amy Covert as Chief Financial Officer first appeared on EW Healthcare Partners.
]]>The post VitalConnect Announces Addition of Heather Getz to Board of Directors first appeared on EW Healthcare Partners.
]]>SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the addition of Heather C. Getz, CPA, MBA, to its Board of Directors. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. Getz has significant expertise in finance, investor relations, compliance, M&A and strategic planning particularly in the cardiac monitoring space.
“Her extensive financial and operational management experience in public and private companies, including strategies for reimbursement, experience with governmental entities like CMS, cost savings, and acquisitions will help us expand our growth in this very competitive market.”
“The addition of Heather Getz to our board brings us significant experience across a broad spectrum of successful companies in the healthcare space,” said Dr. Nersi Nazari, Executive Chairman and Founder, VitalConnect. “Heather has a proven track record of success at BioTelemetry and other healthcare companies with experience driving revenue growth, and acquisitions and integrations, plus securing millions of dollars in financing and we’re excited to welcome her to VitalConnect.”
Getz currently holds the position of Executive Vice President and Chief Financial Officer of Butterfly Network Inc. (NYSE: BFLY), a digital health company that is transforming care with handheld, whole-body ultrasound. She has also held leadership positions at VIASYS Healthcare, Cardinal Health, Alita Pharmaceuticals, Healthy.io and BioTelemetry. For the twelve years, prior to Butterfly Networks, Getz was the Chief Financial Officer and Administrative Officer of BioTelemetry where she was responsible for all aspects of company financial, investor relations, human relations, legal and compliance functions, and worked extensively in strategic planning.
“Heather’s experience and financial acumen brings a wealth of knowledge to our board at VitalConnect and we’re thrilled to have her,” said Peter Van Haur, CEO of VitalConnect. “Her extensive financial and operational management experience in public and private companies, including strategies for reimbursement, experience with governmental entities like CMS, cost savings, and acquisitions will help us expand our growth in this very competitive market.”
Getz holds and Master of Business Administration and a Bachelor’s degree in accountancy from Villanova University. She is a certified public accountant and a member of the American Institute of Certified Public Accountants (CPAs), the Pennsylvania Institute of CPAs and the National Investor Relations Institute.
“I am excited to join the VitalConnect board at such a pivotal time in the company’s history. I have been impressed by the technology and how it has been used to drive more effective clinical outcomes while reducing cost of care and improving patient experience,” said Getz. “I look forward to working with the team to further accelerate the company’s already impressive growth. I am confident VitalConnect is positioned for success in both cardiac monitoring, and the emerging remote patient management market, to deliver exceptional shareholder value.”
Founded in 2011, VitalConnect has deployed more than 200,000 patches throughout the world, including care facilities such as Brigham and Women’s, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital-Oxford University. The VitalPatch allows real-time remote or in-hospital monitoring, allowing physicians to optimize the delivery of care to their patients.
About VitalConnect, Inc.
VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. For more information: www.vitalconnect.com.
Contacts
Media Contacts:
Steve Kelly
VitalConnect, Inc.
206-856-6488
[email protected]
The post VitalConnect Announces Addition of Heather Getz to Board of Directors first appeared on EW Healthcare Partners.
]]>The post EyePoint Pharma Shares Rise 19% After Positive Data for EYP-1901 Trial first appeared on EW Healthcare Partners.
]]>“The final 12-month results from the DAVIO clinical trial highlight EYP-1901’s continued positive safety and efficacy profile with promising durability as a potential every six-month maintenance therapy for previously treated wet AMD,” said Rishi Singh, M.D., a member of EyePoint’s Scientific Advisory Board. “We are grateful to the patients, investigators and site staff who participated in the Phase 1 DAVIO trial.”
“We are extremely pleased with the excellent safety and efficacy results from our Phase 1 DAVIO trial. There remains a significant opportunity for a safe and effective sustained delivery maintenance treatment in wet AMD, and the DAVIO trial demonstrates that EYP-1901 has the potential to maintain a majority of patients for up to six months with no supplemental anti-VEGF therapy,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. “We look forward to beginning to dose patients in the Phase 2 DAVIO2 clinical trial for EYP-1901 in wet AMD and anticipate top line data in the second half of 2023.”
The final twelve-month data presented from the Phase 1 DAVIO clinical trial showed no reports of ocular SAEs or drug-related systemic SAEs. There were no reported events of vitreous floaters, endophthalmitis, retinal detachment, implant migration in the anterior chamber, retinal vasculitis, posterior segment inflammation, or retinal vascular occlusive events. Additionally, updated data from the twelve-month follow-up confirm stable best corrected visual acuity (BCVA) (-4.12 ETDRS letters), stable central subfield thickness (CST) on optical coherence tomography (OCT) (-2.76 μm), and an expected late increase in supplemental anti-VEGF therapy given the insert’s expected drug depletion, with 35% of eyes supplement free up to twelve months versus 53% supplement free up to six months. Additionally, there continued to be positive treatment burden reduction of 74% at twelve months versus 79% at six-months.
EyePoint anticipates that the first patient in the twelve-month, randomized, controlled Phase 2 clinical trial (DAVIO2) of EYP-1901 for wet AMD will be dosed in Q3 2022. The trial is expected to enroll approximately 150 wet AMD patients previously treated with a standard-of-care anti-VEGF therapy and randomly assigned to one of two doses of EYP-1901 (approximately 2 mg or 3 mg) versus an on-label aflibercept control. EYP-1901 is delivered with a single intravitreal injection in the physician’s office, similar to current FDA approved anti-VEGF treatments. The primary efficacy endpoint of the DAVIO2 trial is non-inferiority to the aflibercept control, as measured by change in BCVA six-months after the EYP-1901 injection. Secondary efficacy endpoints include change in CST as measured by OCT, time to first supplemental anti-VEGF, and safety. More information about the study is available at clinicaltrials.gov (identifier: NCT05381948).
About EYP-1901
EYP-1901 is being developed as an investigational sustained delivery treatment, initially in wet age-related macular degeneration (wet AMD) combining a bioerodible formulation of EyePoint’s proprietary Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor. Positive twelve-month safety and efficacy data from the Phase 1 DAVIO clinical trial of EYP-1901 showed no reports of ocular or drug-related systemic serious adverse events and no dose limiting toxicities with stable visual acuity and OCT. Further, 53% of eyes did not require supplemental anti-VEGF injections up to six months following a single dose of EYP-1901. A Phase 2 trial for wet AMD (DAVIO2) is expected in Q3 2022 and Phase 2 studies are planned for non-proliferative diabetic retinopathy and diabetic macular edema in 2H 2022 and 2023, respectively. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases.
About Wet AMD
Age-related macular degeneration (AMD) impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD – the hallmark of which is fluid and bleeding in the center of the retina, which may lead to irreversible vision loss. The majority of patients with wet AMD require intravitreal injections every month or two to control the disease. This intense treatment regimen represents an ongoing challenge for patients, caregivers, and physicians.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients’ eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Forward Looking Statements
EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a sustained delivery intravitreal anti-VEGF treatment for serious eye diseases, including wet age-related macular degeneration; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of our commercialized products, YUTIQ® and DEXYCU®; market acceptance of our products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy; and the impact of general business and economic conditions. More detailed information on these and additional factors that could affect EyePoint’s actual results are described in EyePoint’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
[email protected]
Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
[email protected]
The post EyePoint Pharma Shares Rise 19% After Positive Data for EYP-1901 Trial first appeared on EW Healthcare Partners.
]]>